2 enrolling by invitation. 2 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 2 | Enrolling by invitation 2 |
Follow Lymphoproliferative Disorders: new trials by email Literature Review of Lymphoproliferative Disorders trials Research Report on Lymphoproliferative Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Beyond EOsinophils: proteoMICS to Identify Potential Biomarker of Organ Damage and Response to MEPOLIZUMAB in EGPA Mepolizumab 100 MG Injection [Nucala], Mepolizumab 300 mg - EGPA - Eosinophilic Granulomatosis With Polyangiitis, Severe Asthma | Phase 4 | Enrolling by invitation | Azienda Ospedaliero Universitaria di Cagliari | 90 | 2025-10-17 | 2026-01-15 |
| Exploring the Minimum Effective Concentration and Volume of Ropivacaine for Sacral Plexus Anesthesia Low-dose ropivacaine, Medium-dose of ropivacaine, High-dose ropivacaine - Pediatric ALL | Phase 4 | Enrolling by invitation | Yilin Zhao | 180 | 2024-05-10 | 2024-12-02 |
Asthma (1) · Churg-Strauss Syndrome (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Pulmonary Eosinophilia (1)
Hematologic Diseases (2) · Hemic and Lymphatic Diseases (2) · Immune System Diseases (2) · Lymphatic Diseases (2) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (1) · Autoimmune Diseases (1) · Bronchial Diseases (1) · Cardiovascular Diseases (1) · Eosinophilia (1) · Granuloma (1) · Hypereosinophilic Syndrome (1) · Hypersensitivity (1) · Hypersensitivity, Immediate (1) · Immunoproliferative Disorders (1)
Injections (1) · Magnetic Resonance Spectroscopy (1) · Ropivacaine (1) · mepolizumab (1)
Azienda Ospedaliero Universitaria di Cagliari (1) · Yilin Zhao (1)
China (1) · Italy (1)